SIGNET-RING CELL CARCINOMA

This adverse event was reported 100 times

These drugs are most commonly taken by patients reporting SIGNET-RING CELL CARCINOMA:

# Drug Count
0 ADALIMUMAB 16
1 INFLIXIMAB 16
2 ADALIMUMAB-AATY 10
3 ADALIMUMAB-ADAZ 10
4 ADALIMUMAB-FKJP 10
5 USTEKINUMAB 9
6 PANTOPRAZOLE SODIUM 7
7 AZATHIOPRINE 6
8 LISINOPRIL 6
9 CALCIUM CARBONATE 5
See all common drugs associated with SIGNET-RING CELL CARCINOMA

SIGNET-RING CELL CARCINOMA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Methylating Agent [EPC] 1 0.0010
1 mu-Opioid Receptor Agonist [EPC] 1 0.0003
2 Carnitine Analog [EPC] 1 0.0003
3 Cannabinoid [EPC] 2 0.0002
4 alpha-1 Adrenergic Agonist [EPC] 1 0.0002
5 Glinide [EPC] 2 0.0002
6 Vitamin D2 Analog [EPC] 1 0.0001
7 Allylamine Antifungal [EPC] 1 0.0001
8 Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC] 1 0.0001
9 Phenothiazine [EPC] 3 0.0001
See all drug classes enriched for association with SIGNET-RING CELL CARCINOMA